On the evening of December 28, Guangyuyuan (600771) announced that the company received the "Notice of Case Filing" issued by the China Securities Regulatory Commission, and on December 22, 2023, the China Securities Regulatory Commission decided to file a case against the company due to the company's suspected illegal information disclosure.
Guangyuyuan said that at present, the company's production, operation management and business activities are normal. During the investigation, the company will actively cooperate with the relevant work of the CSRC and fulfill its information disclosure obligations in strict accordance with relevant laws, regulations and regulatory requirements.
In the secondary market, on December 29, Guangyuyuan's share price opened sharply lower, and it fell by more than 8% intraday.
In view of the company's filing, Wu Lijun, a lawyer at Shanghai Haihui Law Firm, said that any injured investors who held Guangyuyuan** on December 28, 2023** may be able to claim compensation from the company. Eligible investors can register for participation through the official account "Dazhong ** Daily" (feature code: 18). The final claim conditions are subject to the court's determination.
According to the information on the company's official website, Guangyuyuan was founded in Jiajing in the Ming Dynasty for 20 years, with a history of nearly 500 years, during which it has gone through more than a dozen business name pharmaceutical factories such as Guangsheng Pharmacy, Guangshengju, Guangshengwei, Guangshengyu, Guangshengyuan, Shanxi Traditional Chinese Medicine Factory, Shanxi Guangyuyuan, etc., and became the first batch of "China Time-honored Brand" enterprises recognized by the Ministry of Commerce of the People's Republic of China in 2006. On November 5, 1996, the company was listed on the Shanghai ** Stock Exchange.
After two consecutive years of losses, Guangyuyuan's performance has improved in 2023. In the first three quarters of this year, the company achieved operating income of 93.8 billion yuan, a year-on-year increase of 1419%；The net profit attributable to the parent company was 24.49 million yuan, compared with a loss of 49.82 million yuan in the same period last year.